Interpreting Alzheimer’s Disease-Associated Genetic Variation at Enhancer Regions

2016-2019

Treating Alzheimer’s disease is one of the greatest challenges we face in the coming years; the disease has the potential to have an enormous impact on human health. Despite its importance, there still are no highly effective treatments for AD, due in large part to a limited understanding of the underlying disease mechanisms. Our laboratory, as a member of CIRCUITS (Consortium to Infer Regulatory Circuits and to Uncover Innovative Therapeutic Strategies), aims to make progress toward a cure using genomic approaches. Starting from recent insights into the genetic basis of Alzheimer’s disease, we will use a combination of machine learning and experimental techniques to systematically work toward the underlying biological processes, cell types, pathways and potential drug targets.

 


Funding to Date

$780,430

Focus

Foundational, Genetic Risk Factors

Researchers

Andreas R. Pfenning, Ph.D.


Related Content: